8-K

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) 
November 8, 2012

ALLIED HEALTHCARE PRODUCTS, INC.

(Exact name of registrant as specified in its charter)

Delaware	0-19266	25-1370721
(State or Other Jurisdiction	(Commission	(IRS Employer
of Incorporation)	File Number)	Identification No.)

1720 Sublette Avenue, St. Louis, Missouri	63110
(Address of principal executive offices)	(Zip Code)

Registrant’s telephone number, including area code 

(314) 771-2400 

Not applicable 

(Former name or former address, if changed since last report) 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

ITEM 7.01. Regulation FD Disclosure.

On November 8, 2012, Allied Healthcare Products, Inc. (the “Company”) is presenting the materials attached to this report as Exhibit 99.1 at its annual stockholder meeting.

ITEM 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.	Description
99.1	Exhibit materials being presented at the Company’s annual stockholder meeting. These materials are being furnished pursuant to Item 7.01 hereof.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	ALLIED HEALTHCARE PRODUCTS, INC.
Date:  November 8, 2012	By:	/s/  Daniel C. Dunn
		Daniel C. Dunn
		Chief Financial Officer

EX-99.1

1 ALLIED HEALTHCARE ANNUAL SHAREHOLDER MEETING November 8, 2012

FY2012 REVIEW ▪ Domestic Hospital, Construction & Emergency Markets Continued to be Hammered by Recession. 2

FY2012 REVIEW - cont ▪ International Sales have begun to turn around. 3 % Change from Prior Year % Change from Pre - Recession Levels International Orders 25.5% 4.7% International Sales 6.2% (9.4)%

MASS CASUALTY PRODUCTS 4 ▪ We have not yet been able to convince the emergency preparedness community to the level we expected of the need for hospital evacuation/mass casualty ventilators: » Can be operated by non - RCPs » Can operate outdoors with rough treatment » Are designed to be stockpiled for extended periods

CO ₂ ABSORBENTS Introduced our CO ₂ Absorbent, Litholyme, in FY2012. 5

FY 2012 FY 2011 $ DIFF Sales $43.4 $46.8 $(3.3) Gross Margin $10.0 $11.0 $(1.0) % 23.0% 23.5% SG&A $10.6 $10.6 ----- Pre - Tax Profit $(0.7) $0.4 $(1.0) % (1.6)% 0.9% EPS $(0.05) $0.03 $(0.08) 6

CHANGE IN PRE - TAX PROFIT FY2012 VS FY2011 Sales Decline of $3.3 Million $(1.6) Increased Material Costs $(0.2) Mfg Cost Reductions $0.7 Other $0.1 Change In Gross Margins $(1.0) SG&A Expense ---- Change in Pre - tax Profit $(1.0) 7

FY2013 ▪ Projecting no significant improvement in Domestic Hospital, Emergency Construction Markets. ▪ Expect to continue to see double digit growth in our international sales. ▪ Expect to see major growth in our CO 2 Absorbent business. ▪ Will be introducing our new AHP300 ventilator in the 4 th quarter. 8

AHP 300 ▪ Expert/Non - Expert Mode: a. Can be used day - to - day as hospital transport vent. b. Can be used in evacuation or mass casualty incident by “non - experts”. ▪ “Stockpileable” ▪ Able to operate outdoors in cold, rain, etc. ▪ Can operate for extended periods on battery. 9

FY2013 OUTLOOK SUMMARY ▪ No expected change in domestic markets. ▪ International sales growth to continue. ▪ Expect significant growth in CO ₂ Absorbent business. ▪ Don’t expect impact of AHP300 until FY 2014. 10